Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Open Label Trial to Evaluate Dolutegravir Versus Efavirenz 400 mg, Both Combined With Tenofovir Disoproxil Fumarate + Lamivudine for the Initial Management of HIV Infected Adults in Resource-limited Settings

NCT02777229 is registered in ClinicalTrials.gov with ANRS, Emerging Infectious Diseases as lead sponsor.

NCT NCT02777229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02777229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Open Label Trial to Evaluate Dolutegravir Versus Efavirenz 400 mg, Both Combined With Tenofovir Disoproxil Fumarate + Lamivudine for the Initial Management of HIV Infected Adults in Resource-limited Settings
Lead sponsor
ANRS, Emerging Infectious Diseases
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2016
Completion date
July 31, 2021
Enrollment
616 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection